Home/Pipeline/AmoyDx Pan Lung Cancer PCR Panel

AmoyDx Pan Lung Cancer PCR Panel

Non-Small Cell Lung Cancer (NSCLC)

CommercialApproved as CDx for multiple therapies (e.g., Capmatinib, Taletrectinib) in China and Japan

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Commercial

Status

Approved as CDx for multiple therapies (e.g., Capmatinib, Taletrectinib) in China and Japan

Company

Amoy Diagnostics

About Amoy Diagnostics

A precision oncology diagnostics company developing PCR and NGS-based companion diagnostic kits for cancer, with a focus on accessibility and global partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active